Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin in MRD+ AML after SCT
NCT03951961Phase 2Terminated
- Sponsor
- Friedrich Schiller University Jena
- Start
- Mar 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of midostaurin in acute myeloid leukemia (AML), sponsored by Friedrich Schiller University Jena. Primary endpoint: Leukemia-free survival at 12 months. Started Mar 2020; status: terminated.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03951961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03951961.